A Randomized, Double-blind, Placebo-controlled Phase 1 Study to Evaluate the Safety, Tolerability and Pharmacokinetics of JX2105 in Healthy Chinese Subjects

PHASE1Enrolling by invitationINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

July 1, 2024

Primary Completion Date

January 30, 2025

Study Completion Date

March 31, 2025

Conditions

Parkinson's Disease

Interventions

DRUG

JX2105

Oral capsule

DRUG

Placebo

Oral capsule

Trial Locations (1)

Beijing Ditan Hospital, Capital Medical University, Beijing

All Listed Sponsors

lead

Zhejiang Jingxin Pharmaceutical Co., Ltd.

INDUSTRY